and 95% (95%CI = 87–98%). Bilateral gonadectomy was performed in 6/77 patients. At a median age (at last update) of 26 years, 28 pregnancies were reported in 19 patients (25 natural, 3 medically-assisted), leading to 23 healthy-born children. Three patients treated with ifosfamide/platinum-based chemotherapy suffered from chronic-kidney-disease. Seven Brock grade-1 and 1 grade-2 ototoxicities were described in patients treated with cisplatinum. Ovarian NS-GCT have an excellent prognosis even in advanced cases with conservative surgery and platinum-based chemotherapy, with few long-term complications.

GCT-27 Pure paediatric ovarian immature teratomas: the French experience

R. Pavone[1], V. Ro[2], F. Dijoud[3], L. Galmiche[4], D. Orbach[5], C. Briandet[6], M. Pasquet[7,8], A. Bertrand[2], B. Fresneau[1,9], C. Faure-Conter[2]
[1]Department of Children and Adolescent oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; [2]Department of Pediatric oncology, Institut d'Hemato-oncologie Pediatrique, Lyon, France; [3]Institut Multisite de Pathologie, CHU de Lyon, France; [4]Laboratoire d'Anatomie Pathologique, Hôpital Necker-Enfants Malades, Paris, France; [5]SIREDO oncology center (Care, Innovation and Research for Children, Adolescents and young Adults with Cancer) Institut Curie, PSL University, Paris, France; [6]Service d'Immuno-Hématologie Pédiatrique, CHU de Dijon, France; [7]Department of Pediatric oncology, CHU de Toulouse, Toulouse, France; [8]INSERM U1037, CRCT, team 16, France; [9]Paris-Saclay University, Paris-Sud University, CESP, INSERM, Villejuif, France

Background: To describe characteristics and outcome of paediatric ovarian immature teratomas (IT), to better define the place of chemotherapy.
Methods: Children with ovarian IT enrolled in TGM-95 and TGM-2013 studies were analysed. Norris grading and FIGO (International Federation of Gynecology and Obstetrics) staging system were used. Gliomatosis peritonei (GP) and mature teratoma peritoneal implants did not result in upstaging, whereas IT peritoneal implants did.
Results: Thirty-seven cases were identified (median age = 11 years): 36/37 stage I (17 stage IA, 14 stage IC and 5 stage IX), including 7 patients with GP, and 1 stage IIIB (IT peritoneal implants). All patients had surgery first: 22 underwent unilateral oophorectomy, 14 unilateral adnexectomy and 1 bilateral cystectomy. No extensive GP surgery was performed. Seven patients received adjuvant VBP (vinblastine-bleomycin-cisplatinum), for tumour rupture (n = 6, 2 had GP) and stage III (n = 1). After a median follow-up of 27 months, 2 events occurred: 1 bilateralization (initial stage IX, grade I) and 1 TI peritoneal relapse (initial stage IA, grade II), 10 and 11 months after diagnosis. Both were successfully treated with platinum-based chemotherapy and delayed surgery. No stage-IC-patients treated without adjuvant chemotherapy relapsed (4 grade I and 3 grade III). None of the 7 GP-patients suffered from progressive disease. Two-year EFS and OS were 94% (95%CI = 80–98%) and 100%. No significant impact of grading on EFS was observed (p = 0.73). The current series confirms the excellent prognosis of paediatric ovarian IT, even with GP or rupture, pleading for conservative surgical approach in GP and against systematic adjuvant chemotherapy, even in ruptured tumours.

GCT-28 Genetic profiling and clonal evolution in ovarian yolk-sac tumours

J. Yang[1]
[1]Dept of Gynecological Oncology, Peiking Union Medical College Hospital, Beijing, China

Background: Yolk-sac tumour (YST) is the most common histological subtype of germ-cell-tumour (GCT). The molecular basis associated with chemo-resistance and genomic evolution under selective pressure from chemotherapy are incompletely characterized.
Methods: We performed whole-exome sequencing on 43 tumour and germline DNA samples from 30 patients with ovarian YST, which were categorized as chemo-sensitive or chemo-resistant group. Among chemo-resistant samples, eight paired sets of primary and relapsed tumours were under clonality analysis.
Results: Mutation rate was low in ovarian YST compared with other solid tumours. Total mutational burden increased with patient age. Primary untreated tumours in chemo-resistant group had higher microsatellite instability than those in chemo-sensitive group, while total mutational burden was not significantly different between two groups. *MUC4* and *BCLAF1* were recurrent mutated in both groups, while *TP53* and *KRAS* alterations were present exclusively in chemo-resistant group and shared both in primary and relapsed samples of two patients. Relapsed tumour samples had significantly increased mutational burden and were characterized by intratumoral heterogeneity. Clonality analysis revealed relapsed ovarian YST evolved either from one of the subclones of primary tumours at a very early timepoint or new clones emerged after initial treatment. This is first whole exome sequencing data of pure ovarian YST. Our data provide genetic-level evidence that patient age is an independent predictor of mortality. We confirmed chemotherapy resistance was associated with *TP53* alterations (previously reported in testicular GCTs). Two different clonal evolution patterns found in relapsed ovarian YST might indicate different multi-step chemo-resistance mechanisms.

GCT-29 Behaviour and outcome of paediatric immature teratomas at children cancer hospital in Egypt. What did we learn over 10 years?

S. Ahmed[1,2], M. Shafiey[3], M. Elwakeel[4], M. Ahmed[5], L. Basiouny[6]
[1]Department of Pediatric Oncology, National Cancer institute, Cairo University, Cairo, Egypt; [2]Department of Pediatric Oncology, Children Cancer Hospital (57357), Cairo, Egypt; [3]Department of Surgical Oncology, Children Cancer Hospital (57357), Cairo, Egypt; [4]Department of Radio-diagnosis, Children Cancer Hospital (57357), Cairo, Egypt; [5]Department of Pathology, Children Cancer Hospital (57357), Cairo, Egypt; [6]Department of Clinical research, Children Cancer Hospital (57357), Cairo, Egypt

Background: Teratomas are derived of more than one germ layer [1]. Based on quantity of immature neuroepithelium they are graded as mature G0 or immature (G1, G2, G3). Teratomas are tumours with variable behaviour depending on age, site, size and pathological grade.
Methods: Records of all new cases with immature teratomas equal or below 18 years of age, treated at Children Cancer Hospital in Egypt over a 10-year period from July 2007 to December 2017, were revised for epidemiology, primary site, stage, pathological grading, management and outcome (OS, EFS).
Results: Teratomas constitute 45% (134/300) of all germ cell tumours, with female predominance (60%), more commonly at extragonadal sites (60%) predominantly sacrococcygeal and retroperitoneal. Ovarian teratomas exceed testicular (66%). Grade 0, 1, 2 and 3 constitutes (63%, 7%, 6% and 24%) respectively with 5 y overall (OS) and event-free survival (EFS) ranged from 100% in grade 1 to 86.2% in grade 3. 10 y OS of high grade immature teratomas was 85.8% in patients <11 years compared with 75% in older age. In conclusion, immature teratoma of high grade carries less favourable outcome. Extensive surgical resection±more aggressive treatment are essential to improve outcome.

Reference

[1] Witschi E., *Migration of the germ cells of human embryos from the yolk sac to the primitive gonadal fold, Contributions to Embryology* (ed. 7), Vol. 32, Carnegie Institution of Washington, Washington, D. C (1948), pp. 67–80.